Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas
Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas
复制标题
DOI：
10.1023/b:neon.0000033385.37098.85
复制
发表时间：
2004-07-01
影响因子：
3.9
通讯作者：
Karayan-Tapon, L
中科院分区：
文献类型：
--
作者：
Blanc, JL;Wager, M;Karayan-Tapon, L
为了扩展 MGMT 启动子甲基化状态与 CENU 治疗反应之间的潜在关系，我们检查了 44 名胶质母细胞瘤患者的 MGMT 启动子甲基化状态。辅助治疗前在手术期间获得肿瘤标本，冷冻并保存在-80℃直至进行DNA提取过程。通过甲基化特异性 PCR (MSP) 确定每个肿瘤中 MGMT 基因 CpG 岛的 DNA 甲基化模式。然后使用统计分析将这些结果与总生存率和对烷化剂的反应相关联。在 68% 的肿瘤中检测到 MGMT 启动子甲基化，96.7% 的甲基化肿瘤也表现出非甲基化状态。 MGMT 启动子的甲基化状态与总体生存率和对烷化剂的反应之间没有关系。我们的观察结果并未导致我们将 MGMT 基因启动子甲基化视为胶质母细胞瘤对烷化剂反应性的预后因素。
In an effort to extend the potential relationship between the methylation status of MGMT promoter and response to CENU therapy, we examined the methylation status of MGMT promoter in 44 patients with glioblastomas. Tumor specimens were obtained during surgery before adjuvant treatment, frozen and stored at -80 degreesC until for DNA extraction process. DNA methylation patterns in the CpG island of the MGMT gene were determined in every tumor by methylation specific PCR (MSP). These results were then related to overall survival and response to alkylating agents using statistical analysis.Methylation of the MGMT promoter was detected in 68% of tumors, and 96.7% of methylated tumors exhibited also an unmethylated status. There was no relationship between the methylation status of the MGMT promoter and overall survival and response to alkylating agents. Our observations do not lead us to consider promoter methylation of MGMT gene as a prognostic factor of responsiveness to alkylating agents in glioblastomas.